Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Clinical Research Bill Unlikely to Clear Diet in Current Session
May 27, 2016
- MHLW to Request Budgets to Promote Venture Companies in Response to Growth Strategy
May 26, 2016
- Pemphigoid Added to List of Clinically Significant Adverse Reactions for DPP-4 Inhibitors: Safety Bulletin
May 26, 2016
- MHLW Working Group Urges Govt to Push NTD Drug Development at Mie Summit
May 25, 2016
- MHLW to Begin Discussions this Fiscal Year on Regulation of Plasma Exports
May 25, 2016
- AZ’s Ticagrelor, Boehringer’s Triple Combo Added to MHLW Panel’s Review Agenda for May 27
May 24, 2016
- Takecab-Contained Blister Packs for H. pylori Eradication, Other Products to Join NHI Price List on May 25
May 24, 2016
- MHLW OKs Add’l Indications for Avastin, Other Drugs
May 24, 2016
- MHLW’s Expanded Development Request Scheme Gets Underway
May 23, 2016
- Lecture Fees Paid “Purely as Compensation” Would Not Be Subject to Regulation under New Clinical Research Bill: Health Policy Bureau Chief
May 23, 2016
- Govt’s Draft Economic Growth Strategy Embraces Use of Big Data by PMDA
May 20, 2016
- Deregulation Panel Calls for Revisiting Plasma Export Restrictions, Wants Conclusion by FY2018
May 20, 2016
- Clinical Research Bill to Make It Easier for Companies to Provide Unapproved Drugs for Clinical Programs: LDP Lawmaker
May 20, 2016
- Council Determines Parathyroid Hormone Preparation for Hypoparathyroidism Has High Unmet Medical Need
May 20, 2016
- MHLW Raises Caution for Use of Harvoni, 7 Other Hep C Drugs in HBV Carriers
May 19, 2016
- Clinical Research Bill to Enter Diet Deliberations on May 20, Might Be Enacted June 1
May 19, 2016
- MOF Panel Recommends Full Rollout of Cost-Effective Evaluations
May 19, 2016
- LDP Bigwig Questions Costly Meds Reimbursement without Politicians’ Input
May 19, 2016
- Draft of Govt’s Economic, Fiscal Policy Blueprint Mentions “Optimal Use of Innovative Drugs”
May 19, 2016
- Standard Operating Profit Rate for Cost Calculation Pricing Rule Updated to 14.6%: Chuikyo
May 19, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…